ATE368054T1 - Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität - Google Patents

Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität

Info

Publication number
ATE368054T1
ATE368054T1 AT98963311T AT98963311T ATE368054T1 AT E368054 T1 ATE368054 T1 AT E368054T1 AT 98963311 T AT98963311 T AT 98963311T AT 98963311 T AT98963311 T AT 98963311T AT E368054 T1 ATE368054 T1 AT E368054T1
Authority
AT
Austria
Prior art keywords
modulating agents
occludin
cell adhesion
methods
compounds
Prior art date
Application number
AT98963311T
Other languages
English (en)
Inventor
Orest W Blaschuk
Barbara Gour
James Matthew Symonds
Original Assignee
Adherex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adherex Technologies Inc filed Critical Adherex Technologies Inc
Application granted granted Critical
Publication of ATE368054T1 publication Critical patent/ATE368054T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT98963311T 1997-12-31 1998-12-30 Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität ATE368054T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/001,511 US6248864B1 (en) 1997-12-31 1997-12-31 Compounds and methods and modulating tissue permeability

Publications (1)

Publication Number Publication Date
ATE368054T1 true ATE368054T1 (de) 2007-08-15

Family

ID=21696412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963311T ATE368054T1 (de) 1997-12-31 1998-12-30 Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität

Country Status (9)

Country Link
US (3) US6248864B1 (de)
EP (1) EP1042365B1 (de)
JP (1) JP2002509073A (de)
AT (1) ATE368054T1 (de)
AU (1) AU764790B2 (de)
CA (1) CA2351624A1 (de)
DE (1) DE69838147T2 (de)
ES (1) ES2292211T3 (de)
WO (1) WO1999035166A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797807B1 (en) * 1997-12-31 2004-09-28 Adherex Technologies, Inc. Compounds and methods for cancer therapy
ES2341926T3 (es) * 1998-03-02 2010-06-29 Massachusetts Institute Of Technology Poliproteinas con dedos de cinc que tienen enlazadores mejorados.
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
DK1207905T3 (da) * 1999-09-03 2011-01-03 Brigham & Womens Hospital Fremgangsmåder og sammensætninger til behandling af inflammatorisk sygdom under anvendelse af cadherin-II modulerende midler
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US20030153015A1 (en) * 2000-01-20 2003-08-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ATE355368T1 (de) * 2000-01-24 2006-03-15 Gendaq Ltd Nucleinsäure bindende polypeptide gekennzeichnet durch flexible linker verbundene nucleinsäuredomäne
US20030195707A1 (en) * 2000-05-25 2003-10-16 Schork Nicholas J Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
US20020077775A1 (en) * 2000-05-25 2002-06-20 Schork Nicholas J. Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
EP1309682A2 (de) * 2000-07-14 2003-05-14 Chiron Corporation Tetraspan protein und dessen verwendung
AU2002226075A1 (en) * 2000-10-23 2002-05-06 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
US20020192206A1 (en) * 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
IL160229A0 (en) * 2001-08-10 2004-07-25 Genset Sa Polynucleotides, polypeptides encoded thereby and their use
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003247435A1 (en) * 2002-05-30 2003-12-19 European Molecular Biology Laboratory Combinatorial chemical library ii
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
EP1384469A1 (de) * 2002-07-25 2004-01-28 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Tight Junctions
EP1384468A1 (de) * 2002-07-25 2004-01-28 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Tight Junctions
AU2003298475A1 (en) * 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
CA2504768A1 (en) * 2002-11-14 2004-05-27 Adherex Technologies, Inc. Compounds and methods for modulating functions of classical cadherins
WO2004098647A2 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins’ underexpression as markers of tumor metastasis
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US20080125364A1 (en) * 2004-12-28 2008-05-29 Asma Nusrat Methods and Compositions for Treating Epithelial Cancers
CA2763671A1 (en) * 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
JP5583003B2 (ja) 2007-04-02 2014-09-03 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
NZ583369A (en) 2007-08-23 2011-08-26 Theracos Inc Benzylbenzene derivatives and methods of use
WO2009102367A2 (en) * 2007-11-19 2009-08-20 The Regents Of The University Of Colorado Tight junction protein modulators and uses thereof
AU2009270936B2 (en) 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
CN103910702A (zh) 2008-08-22 2014-07-09 泰拉科斯有限公司 制备sglt2抑制剂的方法
WO2010040001A1 (en) * 2008-10-03 2010-04-08 The Rockefeller University New hcv entry factor, occludin
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
CA2764526A1 (en) 2009-06-24 2010-12-29 Christine Kritikou The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
JP6086326B2 (ja) 2010-05-24 2017-03-01 ユニヴァーシティー オブ ロチェスター 二環式ヘテロアリールキナーゼ阻害剤および使用方法
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2654757A1 (de) 2010-12-22 2013-10-30 Entarco SA Verwendung von spinosynen und spinosynzusammensetzungen als lokalanästhetika und antiarrhythmika
EP3502236B1 (de) 2011-02-18 2023-08-23 The Scripps Research Institute Gezielte differenzierung von oligodendrozyten-vorläuferzellen zu einem myelinierungszellenschicksal
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
EP3103808B1 (de) * 2014-02-07 2018-08-22 Miyarisan Pharmaceutical Co., Ltd. Peptid mit aktivität zur hemmung der produktion von toxins durch bakterium der gattung clostridium
EP3119394B1 (de) 2014-03-19 2021-05-12 Curza Global LLC Zusammensetzungen und verfahren mit 2-(acylamino)imidazolen
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
CN108084257B (zh) * 2016-11-23 2020-06-12 深圳市安群生物工程有限公司 人闭锁蛋白抗原表位肽、抗原、抗体、试剂盒及应用
JP2020512981A (ja) 2017-03-31 2020-04-30 カーザ グローバル，リミティド ライアビリティ カンパニー 置換２−アミノイミダゾールを含む組成物と方法
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
WO2022098972A1 (en) 2020-11-08 2022-05-12 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
EP4320160A1 (de) 2021-04-09 2024-02-14 Seagen Inc. Verfahren zur behandlung von krebs mit anti-tigit-antikörpern
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2024225703A1 (ko) * 2023-04-26 2024-10-31 서울대학교산학협력단 C-n 결합으로 환형화된 새로운 환형 펩타이드계열 화합물, 이의 생산 방법 및 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1464703A3 (de) 1996-03-07 2004-10-13 Eisai Co., Ltd. Adhäsionsmolekül Occludin vom Hund
US6252045B1 (en) 1996-03-15 2001-06-26 Yale University Human occludin, its uses and enhancement of drug absorption using occludin inhibitors
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity

Also Published As

Publication number Publication date
CA2351624A1 (en) 1999-07-15
AU1866599A (en) 1999-07-26
EP1042365B1 (de) 2007-07-25
JP2002509073A (ja) 2002-03-26
DE69838147T2 (de) 2008-05-29
WO1999035166A1 (en) 1999-07-15
US6248864B1 (en) 2001-06-19
US6110747A (en) 2000-08-29
EP1042365A1 (de) 2000-10-11
AU764790B2 (en) 2003-08-28
US6310177B1 (en) 2001-10-30
ES2292211T3 (es) 2008-03-01
DE69838147D1 (de) 2007-09-06

Similar Documents

Publication Publication Date Title
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE69832293D1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
DE60332277D1 (de) Verabreichung von sirnas
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
ATE410441T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60006100D1 (de) Lang wirkende insulinotrope peptide
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60032486D1 (de) Prion protein peptide und deren verwendung
WO2000002917A3 (en) Compounds and methods for modulating cadherin-mediated functions
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
EP1401467A4 (de) Alpha-fetoprotein-peptide und ihre verwendung
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE414100T1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties